Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 8.80 as of 2026-10-06T14:31:21.711Z.
Consensus retrieved: 2026-10-06T10:36:17.779Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:31:21.711Z.
Quote observation: 2026-10-06T14:17:44.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e47236677832b0178bb4e4de0ecbdefb2e069a6eb9feaf5a3a870b06349bdf9c
Forward PE Ratio (8.80) = Dated Quote Price ($0.88) / Consensus Forward EPS ($0.10)
FORWARD PE RATIO
8.80
SECTOR MEDIAN · HEALTHCARE
19.32
median of 154 covered companies
CURRENT VS SECTOR MEDIAN
-54.46%
vs the sector median at left
Citius Oncology, Inc.
Market Cap
$81.83M
Forward PE Ratio
8.80
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Citius Oncology, Inc. (CTOR) | $81.83M | 8.80 |
| LENSAR Inc (LNSR)vs › | $81.43M | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $82.61M | N/A |
| MediciNova, Inc. (MNOV)vs › | $82.69M | N/A |
| Pulmonx Corporation (LUNG)vs › | $79.62M | N/A |
| Humacyte, Inc. (HUMA)vs › | $84.13M | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.15M | N/A |
| Nutriband Inc. (NTRB)vs › | $84.24M | 4.41 |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $79.11M | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.58M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
8.8
consensus EPS · fiscal year ending 2027-09-30
At the dated quote price of $0.88, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-09-30 | $0.10 | $0.10 – $0.10 | 1 | 8.8x |
| 2028-09-30 | $0.46 | $0.46 – $0.46 | 1 | 1.9x |
| 2029-09-30 | $0.53 | $0.53 – $0.53 | 1 | 1.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
